Ophthotech Expands Eye Disease Pipelines of Small Molecule, Gene Therapy Candidates

Ophthotech has expanded its eye disease treatment pipeline today by acquiring a small-molecule, age-related retinal disease therapy developer, as well as launching its third gene therapy collaboration, which will focus on treating the rare retinal disorder Best vitelliform macular dystrophy (Best disease).Ophthotech said it has acquired Inception 4, a privately-held “build-to-buy” company backed by Versant Ventures, and launched in 2013 by Versant with Bayer. Build-to-buy companies a